STOCK TITAN

ImmunityBio Inc - IBRX STOCK NEWS

Welcome to our dedicated news page for ImmunityBio (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ImmunityBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ImmunityBio's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.02%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
none
-
Rhea-AI Summary
ImmunityBio, Inc. announced findings from a Phase 1 study showing that allogeneic CIML NK cells used in combination with ImmunityBio's IL-15 superagonist N-803 may induce tumor regression in advanced head-and-neck cancer patients. The study demonstrated the potential for a new treatment approach for the disease in cases that currently have poor prognoses. The results were presented at a conference and showed tumor regression associated with expansion of NK cells with cytolytic activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.08%
Tags
none
ImmunityBio Inc

Nasdaq:IBRX

IBRX Rankings

IBRX Stock Data

3.46B
145.27M
79.62%
8.85%
8.09%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About IBRX

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.